Among the most robust findings in the validation phase were elevated serum levels of PRDX6, FCGR3A and APEH, particularly in PPMS patients, —and increased BST1 levels in ROMS patients. The gene discussed is PRDX6; the disease is primary progressive multiple sclerosis.